Anti-IgE treatment of eosinophil-associated gastrointestinal disorders

Journal of Allergy and Clinical Immunology

Volumn 120, Issue 3, 2007, Pages 594-601

  Foroughi, Shabnam ^a   Foster, Barbara ^a   Kim, NaYoung ^a   Bernardino, Leigh B ^a   Scott, Linda M ^a   Hamilton, Robert G ^b   Metcalfe, Dean D ^a   Mannon, Peter J ^a   Prussin, Calman ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

basophil; Eosinophil; eosinophilic esophagitis; eosinophilic gastroenteritis; food allergy; IgE; omalizumab

Indexed keywords

BUDESONIDE; CETIRIZINE; DOXEPIN; ESOMEPRAZOLE; FEXOFENADINE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; KETOTIFEN; LANSOPRAZOLE; LORATADINE; MONTELUKAST; OMALIZUMAB; OMEPRAZOLE; PREDNISONE;

ADULT; ARTICLE; BASOPHIL; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DUODENUM; EOSINOPHIL COUNT; EOSINOPHILIC GASTROINTESTINAL DISORDER; ERYTHEMA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; SKIN TEST; STATISTICAL SIGNIFICANCE; STOMACH ANTRUM; URTICARIA;

ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BASOPHILS; EOSINOPHILIA; EOSINOPHILS; FEMALE; FLOW CYTOMETRY; GASTROENTERITIS; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; SKIN TESTS;

EID: 34548257315     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.06.015     Document Type: Article

References (21)

1. Rothenberg M.E. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 113 (2004) 11-28
2. Spergel J.M., Beausoleil J.L., Mascarenhas M., and Liacouras C.A. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 109 (2002) 363-368
3. Markowitz J.E., Spergel J.M., Ruchelli E., and Liacouras C.A. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 98 (2003) 777-782
4. Blanchard C., Wang N., and Rothenberg M.E. Eosinophilic esophagitis: pathogenesis, genetics, and therapy. J Allergy Clin Immunol 118 (2006) 1054-1059
5. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., and Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115 (2005) 459-465
6. Leung D.Y., Sampson H.A., Yunginger J.W., Burks Jr. A.W., Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348 (2003) 986-993
7. Noga O., Hanf G., and Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 131 (2003) 46-52
8. Djukanovic R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170 (2004) 583-593
9. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 114 (2004) 527-530
10. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., Ren S., et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19 (2003) 491-498
11. Sainte-Laudy J., Sabbah A., Vallon C., and Guerin J.C. Analysis of anti-IgE and allergen induced human basophil activation by flow cytometry. Comparison with histamine release. Inflamm Res 47 (1998) 401-408
12. Foster B., Metcalfe D.D., and Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcεRI: correlation with serum IgE and allergic asthma. J Allergy Clin Immunol 112 (2003) 1132-1138
13. Prussin C., Griffith D.T., Boesel K.M., Lin H., Foster B., and Casale T.B. Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 112 (2003) 1147-1154
14. Hamilton R.G., Marcotte G.V., and Saini S.S. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 303 (2005) 81-91
15. Yoshida E.M. The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 13 (1999) 65-73
16. Konikoff M.R., Blanchard C., Kirby C., Buckmeier B.K., Cohen M.B., Heubi J.E., et al. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin Gastroenterol Hepatol 4 (2006) 1328-1336
17. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158 (1997) 1438-1445
18. Sanz M.L., Gamboa P.M., Antepara I., Uasuf C., Vila L., Garcia-Aviles C., et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 32 (2002) 277-286
19. Sampson H.A., Broadbent K.R., and Bernhisel-Broadbent J. Spontaneous release of histamine from basophils and histamine-releasing factor in patients with atopic dermatitis and food hypersensitivity. N Engl J Med 321 (1989) 228-232
20. Shreffler W.G. Evaluation of basophil activation in food allergy: present and future applications. Curr Opin Allergy Clin Immunol 6 (2006) 226-233
21. Vasagar K., Vonakis B.M., Gober L.M., Viksman A., Gibbons Jr. S.P., and Saini S.S. Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 36 (2006) 770-776